UBS raised the firm’s price target on Glaukos (GKOS) to $145 from $140 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target raised to $145 from $120 at Truist
- Seaport Research healthcare analyst holds analyst/industry conference call
- Glaukos price target raised to $125 from $113 at Citi
- Glaukos price target raised to $125 from $117 at Needham
- Positive Outlook for Glaukos: Buy Rating Reinforced by Epioxa’s Market Potential and Increased Price Target